<DOC>
	<DOCNO>NCT00003649</DOCNO>
	<brief_summary>RATIONALE : Exposing tumor cell p53 gene may improve body 's ability fight non-small cell lung cancer . PURPOSE : Phase I trial study effectiveness gene therapy treat patient non-small cell lung cancer surgically remove .</brief_summary>
	<brief_title>Gene Therapy Treating Patients With Non-Small Cell Lung Cancer That Can Be Surgically Removed</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate safety multiple endobronchial treatment adenovirus p53 bronchoalveolar lavage single lobe lung patient bronchoalveolar cell lung carcinoma . - Evaluate expression p53 gene induction apoptosis tumor normal tissue expose virus patient . - Evaluate whether transbronchial administration adenovirus p53 result improve local tumor control patient . OUTLINE : This dose escalation study . Patients undergo biopsy receive adenovirus p53 bronchoalveolar lavage day 1 15 . Patients repeat biopsy day 3 28 . If evidence clinical benefit response without significant toxicity , patient may receive maximum 3 course . Treatment beyond 3 course must approve protocol investigator . Cohorts 3 patient treat escalate dose level adenovirus p53 . Patients cohort follow dose limit toxicity ( DLT ) 2 week completion one course dose escalation proceeds subsequent cohort . If 1 3 patient dose level experience dose limit toxicity ( DLT ) , 2 additional patient enter dose level . If 1 5 patient experience DLT , previous dose maximum tolerate dose ( MTD ) . An additional 10 patient treated MTD . Patients follow every 3 month first 2 year , every 6 month next 3 year , annually thereafter . PROJECTED ACCRUAL : There 15 patient accrue study 1 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable nonsmall cell lung cancer growth pattern allow access majority tumor cell via airway ( e.g. , bronchioloalveolar papillary adenocarcinoma ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 12 week Hematopoietic : Platelet count great 100,000/mm^3 Prothrombin time partial thromboplastin time normal Hepatic : Bilirubin le 1.5 mg/dL Renal : Creatinine le 1.5 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease Pulmonary : Room air oxygen saturation great 90 % FEV1 great 1.0 L pCO2 le 50 Other : HIV negative No active systemic viral , bacterial , fungal infection require treatment No concurrent illness require hospitalization intravenous medication Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No prior adenovirus gene therapy At least 2 week since systemic biologic therapy include prior biologic response modifier recover Chemotherapy : At least 2 week since prior systemic chemotherapy recover Endocrine therapy : Recovered prior endocrine therapy Radiotherapy : Recovered prior radiotherapy Surgery : At least 2 week since surgical procedure require anesthesia At least 4 week since prior surgical resection lung tissue Other : No concurrent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2002</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>